Heavier FTC Scrutiny Puts Pressure On Consumer Health Product Claims
This article was originally published in The Tan Sheet
Executive Summary
Attorneys say marketers should make structure/function claims with knowledge that no claims are safe from FTC scrutiny. During the Food & Drug Law Institute annual meeting, stakeholders commented on how FTC’s stance on Bayer Health Care’s Philips Colon Health will impact other claims.
You may also be interested in...
FTC Requests Drug Claim Support For Bayer Probiotic Supplement
On behalf of the FTC, DoJ alleges Bayer violated a 2007 settlement to substantiate supplement claims and asks a court to require the firm to provide two RCTs for dietary supplement claims for Phillips’ Colon Health. Trade groups rally behind the firm, arguing the requirement is unfair and illegal.
Sanofi Counts On OTC Switches Adding $1bn In Consumer Revenues By 2026
Sanofi eyes $1bn top line growth from OTC switches of ED drug Cialis and flu drug Tamiflu after they launch by 2026, says CEO Paul Hudson. Like switch consultants, though, he acknowledges the high bar for approval moving additional Rx ingredients to OTC.
Homeopathic Firm's Teething Remedy Touches FDA Enforcement Nerve
FDA warns OHM Pharma for promoting topical formula containing homeopathic ingredients as teething product for infants. The firm also warned about drug and supplements GMP violations and was an easy target for FDA following release of draft guidance outlining its enforcement priorities.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: